ZYUS Life Sciences (TSXV:ZYUS) Cash-to-Debt : 0.60 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is ZYUS Life Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ZYUS Life Sciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.60.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, ZYUS Life Sciences couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for ZYUS Life Sciences's Cash-to-Debt or its related term are showing as below:

TSXV:ZYUS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.3 Max: 0.6
Current: 0.6

During the past 3 years, ZYUS Life Sciences's highest Cash to Debt Ratio was 0.60. The lowest was 0.01. And the median was 0.30.

TSXV:ZYUS's Cash-to-Debt is ranked worse than
58.29% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs TSXV:ZYUS: 0.60

ZYUS Life Sciences Cash-to-Debt Historical Data

The historical data trend for ZYUS Life Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

ZYUS Life Sciences Cash-to-Debt Chart

ZYUS Life Sciences Annual Data

Trend

Dec21

Dec22

Dec23

Cash-to-Debt

N/A

0.01

0.60

ZYUS Life Sciences Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial				0.01	0.02	1.59	0.84	0.60

Competitive Comparison of ZYUS Life Sciences's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ZYUS Life Sciences's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where ZYUS Life Sciences's Cash-to-Debt falls into.

ZYUS Life Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

ZYUS Life Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.852	/	(6.553	+	3.253)
	=	0.60

ZYUS Life Sciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	5.852	/	(6.553	+	3.253)
	=	0.60

ZYUS Life Sciences (TSXV:ZYUS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

ZYUS Life Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of ZYUS Life Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

ZYUS Life Sciences (TSXV:ZYUS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ZYUS Life Sciences Corp (TSXV:ZYUS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ZLSCF:USA

Address

407 Downey Road, Unit 204, Saskatoon, SK, CAN, S7N 4L8

Website

https://www.zyus.com

ZYUS Life Sciences Corp is a next-generation life sciences company engaged in scientific research and development in phyto-therapeutics, including cannabinoid and protein-based formulations. It is committed to delivering high-quality standardized therapeutic formulations that comply with Good Manufacturing Practices (GMP) to provide targeted relief for patients in Canada and globally.

Executives

John Michael Hyshka

Senior Officer

ZYUS Life Sciences (TSXV:ZYUS) Headlines

No Headlines